Skip to main content

Regeneron Pharmaceuticals(REGN-Q)

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low724.12
Day High740.18
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.


A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.


What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.


A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Press & news

Latest News

High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023
PR Newswire - Fri May 19, 2:32PM CDT
PR Newswire
Fri May 19, 2:32PM CDT
/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. and Society for Science (the Society) announced that Kaitlyn Wang, 17, of San José, CA, won the $75,000 top...
2 Cathie Wood Stocks That Can Get You Through Any Recession
Motley Fool - Wed May 10, 8:53AM CDT
Motley Fool
Wed May 10, 8:53AM CDT
Shares of both companies moved higher even as the stock market fell last year.
Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales
MarketBeat - Fri May 5, 5:35AM CDT
Fri May 5, 5:35AM CDT
Regeneron reported better-than-expected Q1 earnings and revenue, but its Eylea sales fell, losing ground to Roche's newly launched Vabysmo.

Latest Articles